ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

Cite this: Chem. Res. Toxicol. 1990, 3, 4, 363–371
Publication Date (Print):July 1, 1990
    ACS Legacy Archive

    Article Views





    Other access options

    Note: In lieu of an abstract, this is the article's first page.

    Free first page

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 218 publications.

    1. M. Saeed Mirzaei, Maxim V. Ivanov, Avat Arman Taherpour, Saber Mirzaei. Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights. Chemical Research in Toxicology 2021, 34 (4) , 959-987.
    2. F. Peter Guengerich, Francis K. Yoshimoto. Formation and Cleavage of C–C Bonds by Enzymatic Oxidation–Reduction Reactions. Chemical Reviews 2018, 118 (14) , 6573-6655.
    3. Tomohisa Tokunaga, Bunta Watanabe, Sho Sato, Jun Kawamoto, and Tatsuo Kurihara . Synthesis and Functional Assessment of a Novel Fatty Acid Probe, ω-Ethynyl Eicosapentaenoic Acid Analog, to Analyze the in Vivo Behavior of Eicosapentaenoic Acid. Bioconjugate Chemistry 2017, 28 (8) , 2077-2085.
    4. Hajime Hirao, Zhi Hao Cheong, and Xiaoqing Wang . Pivotal Role of Water in Terminating Enzymatic Function: A Density Functional Theory Study of the Mechanism-Based Inactivation of Cytochromes P450. The Journal of Physical Chemistry B 2012, 116 (27) , 7787-7794.
    5. Nao Torimoto,, Itsuko Ishii,, Masayuki Hata,, Hiroyoshi Nakamura,, Hiroshi Imada,, Noritaka Ariyoshi,, Shigeru Ohmori,, Takashi Igarashi, and, Mitsukazu Kitada. Direct Interaction between Substrates and Endogenous Steroids in the Active Site May Change the Activity of Cytochrome P450 3A4. Biochemistry 2003, 42 (51) , 15068-15077.
    6. Emadeldin M. Kamel, Ahmed M. Tawfeek, Ashraf A. El-Bassuony, Al Mokhtar Lamsabhi. Mechanistic insights into chloramphenicol-mediated inactivation of cytochrome P450 enzymes and their active site mutants. New Journal of Chemistry 2023, 47 (35) , 16429-16443.
    7. Ilaria Campesi, Flavia Franconi. Human male and female phenotypes depend on lifestyle (smoking and hormonal contraceptives): Implications for prevention and care. 2023, 869-886.
    8. DAN A. ROCK, LARRY C. WIENKERS. Characterization of Cytochrome P450 Mechanism Based Inhibition. 2022, 465-526.
    9. UMESH M. HANUMEGOWDA, CARL DAVIS. The Role of Drug Metabolism in Toxicity. 2022, 605-676.
    10. Hendrik‐Tobias Arkenau, Donatienne Taylor, Xiaoying Xu, Shripad Chitnis, Casilda Llacer‐Perez, Kathleen Moore, Prasanna Kumar Nidamarthy, Palanichamy Ilankumaran, Judith De Vos‐Geelen. Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors. Clinical Pharmacology in Drug Development 2022, 11 (5) , 585-596.
    11. Zhaorui Song, Xinhui Zhai, Chenrui Jiang, Rong Chen, Sijing Ye, Jinzhe Tong, Pierre Dramou, Hua He. Sensitive and selective detection of carbamazepine in serum samples by bionic double-antibody sandwich method based on cucurbit[7]uril and molecular imprinted polymers. Biosensors and Bioelectronics 2022, 203 , 114037.
    12. F. Peter Guengerich. Drug Metabolism: Cytochrome P450. 2022, 470-508.
    13. F. Peter Guengerich. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomolecules & Therapeutics 2022, 30 (1) , 1-18.
    14. Slobodan P. Rendic, F. Peter Guengerich. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Archives of Toxicology 2021, 95 (2) , 395-472.
    15. Michael Mohutsky, Stephen D. Hall. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions. 2021, 51-88.
    16. F. Peter Guengerich. Drug Metabolism: Cytochrome P450. 2021
    17. Hirotaka Kushida, Takashi Matsumoto, Yasushi Ikarashi, Hiroaki Nishimura, Masahiro Yamamoto. Gender differences in plasma pharmacokinetics and hepatic metabolism of geissoschizine methyl ether from Uncaria hook in rats. Journal of Ethnopharmacology 2021, 264 , 113354.
    18. F. Peter Guengerich, Kevin D. McCarty, Jesse G. Chapman. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process. Journal of Biological Chemistry 2021, 296 , 100223.
    19. Sandra Ortega Ugalde, Kerstin Wallraven, Alexander Speer, Wilbert Bitter, Tom N. Grossmann, Jan N.M. Commandeur. Acetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis. Biochemical Pharmacology 2020, 177 , 113938.
    20. Jaydeep Yadav, Erickson Paragas, Ken Korzekwa, Swati Nagar. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacology & Therapeutics 2020, 206 , 107449.
    21. Paul R. Ortiz de Montellano. Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation. Drug Metabolism Reviews 2019, 51 (2) , 162-177.
    22. Ruya Wang, Yanru Cui, Fan Hu, Wei Liu, Qiuzheng Du, Yan Zhang, Jun Zha, Tao Huang, Meriem Fizir, Hua He. Selective recognition and enrichment of carbamazepine in biological samples by magnetic imprinted polymer based on reversible addition-fragmentation chain transfer polymerization. Journal of Chromatography A 2019, 1591 , 62-70.
    23. Ganesh Chandra Jagetia. Treatment of Mice with Naringin Alleviates the Doxorubicin-Induced Oxidative Stress in the Liver of Swiss Albino Mice. MOJ Anatomy & Physiology 2017, 4 (2)
    24. Herbert Kuhl, Inka Wiegratz. Das Post-Finasterid-Syndrom. Gynäkologische Endokrinologie 2017, 15 (2) , 153-163.
    25. Yuan Wei, Chenxiao Tang, Vinayak Sant, Song Li, Samuel M. Poloyac, Wen Xie. A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?. Current Pharmacology Reports 2016, 2 (4) , 187-192.
    26. . Introduction to Human Cytochrome P450 Superfamily. 2016, 1-100.
    27. . Hormonal contraceptives—oral. 2016, 782-823.
    28. Julia Winkler, Mark Goldammer, Matthias Ludwig, Beate Rohde, Christian Zurth. Pharmacokinetic drug–drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. European Journal of Drug Metabolism and Pharmacokinetics 2015, 40 (4) , 389-399.
    29. Yuan Chen, Jialin Mao, Adrian J. Fretland. Reaction Phenotyping. 2015, 1-26.
    30. Christian Zurth, Barbara Schuett, Manuela Casjens, Matthias Ludwig, Katrin Waellnitz. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single‐center, open‐label, randomized, crossover study. Clinical Pharmacology in Drug Development 2015, 4 (4) , 245-255.
    31. Maria Almira Correia, Paul. F. Hollenberg. Inhibition of Cytochrome P450 Enzymes. 2015, 177-259.
    32. F. Peter Guengerich. Human Cytochrome P450 Enzymes. 2015, 523-785.
    33. Victoria Tittle, Lauren Bull, Marta Boffito, Nneka Nwokolo. Pharmacokinetic and Pharmacodynamic Drug Interactions Between Antiretrovirals and Oral Contraceptives. Clinical Pharmacokinetics 2015, 54 (1) , 23-34.
    34. Hiromi Shibasaki, Miyuki Kuroiwa, Shinobu Uchikura, Sayuri Tsuboyama, Akitomo Yokokawa, Miyoko Kume, Takashi Furuta. Use of endogenous cortisol 6β-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors. Steroids 2014, 87 , 137-144.
    35. Frank Z. Stanczyk, David F. Archer. Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception 2014, 89 (4) , 242-252.
    36. Michael Mohutsky, Stephen D. Hall. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions. 2014, 57-91.
    37. David C Lamb, Michael R Waterman, Bin Zhao. Streptomyces cytochromes P450: applications in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 2013, 9 (10) , 1279-1294.
    38. Junichi Iwamoto, Yoshifumi Saito, Akira Honda, Teruo Miyazaki, Tadashi Ikegami, Yasushi Matsuzaki. Bile Acid Malabsorption Deactivates Pregnane X Receptor in Patients with Crohn’s Disease. Inflammatory Bowel Diseases 2013, 19 (6) , 1278-1284.
    39. Amin Kamel, Shawn Harriman. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discovery Today: Technologies 2013, 10 (1) , e177-e189.
    40. Anne Gompel. La contraception estroprogestative remise en cause ?. La Presse Médicale 2013, 42 (3) , 249-252.
    41. Willi Cawello, Bernd Rosenkranz, Bernhard Schmid, Werner Wierich. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia 2013, 54 (3) , 530-536.
    42. F. Peter Guengerich. Cytochrome P450 Activation of Toxins and Hepatotoxicity. 2013, 15-33.
    43. Qian Cheng, Christal D. Sohl, Francis K. Yoshimoto, F.Peter Guengerich. Oxidation of Dihydrotestosterone by Human Cytochromes P450 19A1 and 3A4. Journal of Biological Chemistry 2012, 287 (35) , 29554-29567.
    44. Veronique Michaud, Tamara Bar-Magen, Jacques Turgeon, David Flockhart, Zeruesenay Desta, Mark A. Wainberg, . The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological Reviews 2012, 64 (3) , 803-833.
    45. Fengyan Liu, Steve Wiseman, Yi Wan, Jonathan A. Doering, Markus Hecker, Michael H.W. Lam, John P. Giesy. Multi-species comparison of the mechanism of biotransformation of MeO-BDEs to OH-BDEs in fish. Aquatic Toxicology 2012, 114-115 , 182-188.
    46. Estabelle S.M. Ang, Xiaohong Yang, Honghui Chen, Qian Liu, Ming H. Zheng, Jiake Xu. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation. FEBS Letters 2011, 585 (17) , 2755-2762.
    47. Akira Honda, Teruo Miyazaki, Tadashi Ikegami, Junichi Iwamoto, Tomomi Maeda, Takeshi Hirayama, Yoshifumi Saito, Tamio Teramoto, Yasushi Matsuzaki. Cholesterol 25-hydroxylation activity of CYP3A. Journal of Lipid Research 2011, 52 (8) , 1509-1516.
    48. Raku Shinkyo, F. Peter Guengerich. Inhibition of Human Cytochrome P450 3A4 by Cholesterol. Journal of Biological Chemistry 2011, 286 (21) , 18426-18433.
    49. Graham F. Smith. Designing Drugs to Avoid Toxicity. 2011, 1-47.
    50. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P 450 Mechanism‐Based Inhibition. 2010, 1-56.
    51. Carl D. Davis, Umesh M. Hanumegowda. The Role of Drug Metabolism in Toxicity. 2010, 1-68.
    52. Ramesh B. Bambal, Stephen E. Clarke. Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 2009, 55-107.
    53. . Environmental and Endogenous Factors Determining the Expression of Toxicity. 2009
    54. Yan-Yan Zhang, Ling Yang. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opinion on Drug Metabolism & Toxicology 2009, 5 (6) , 621-629.
    55. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P450 Mechanism‐Based Inhibition. 2009, 479-534.
    56. Carl D. Davis, Umesh M. Hanumegowda. The Role of Drug Metabolism in Toxicity. 2009, 559-628.
    58. MJ Kennedy. Hormonal Regulation of Hepatic Drug-Metabolizing Enzyme Activity During Adolescence. Clinical Pharmacology & Therapeutics 2008, 84 (6) , 662-673.
    59. Zakia Bibi. Role of cytochrome P450 in drug interactions. Nutrition & Metabolism 2008, 5 (1)
    60. Olavi Pelkonen, Miia Turpeinen, Jukka Hakkola, Paavo Honkakoski, Janne Hukkanen, Hannu Raunio. Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology 2008, 82 (10) , 667-715.
    61. Johanna Hilli, Tuomas Korhonen, Miia Turpeinen, Juho Hokkanen, Sampo Mattila, Kari Laine. The Effect of Oral Contraceptives on the Pharmacokinetics of Melatonin in Healthy Subjects With CYP1A2 g.‐163C>A Polymorphism. The Journal of Clinical Pharmacology 2008, 48 (8) , 986-994.
    62. Iris Karunker, Juergen Benting, Bettina Lueke, Tanja Ponge, Ralf Nauen, Emmanouil Roditakis, John Vontas, Kevin Gorman, Ian Denholm, Shai Morin. Over-expression of cytochrome P450 CYP6CM1 is associated with high resistance to imidacloprid in the B and Q biotypes of Bemisia tabaci (Hemiptera: Aleyrodidae). Insect Biochemistry and Molecular Biology 2008, 38 (6) , 634-644.
    63. Sonia M. Poli. Irreversible Cytochrome P450 Inhibition: Common Substructures and Implications for Drug Development. 2008, 267-276.
    64. Dan Rock, Jan Wahlstrom, Larry Wienkers. Cytochrome P450s: Drug–Drug Interactions. 2008, 195-246.
    65. Sharon E. Murphy, Linda B. von Weymarn. Mechanism-Based Inactivation of Cytochrome P450 2A and 2B Enzymes. 2008, 1-29.
    66. William W. Johnson. Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance. Drug Metabolism Reviews 2008, 40 (1) , 101-147.
    67. Shu-Feng Zhou, Charlie Changli Xue, Xue-Qing Yu, Chunguang Li, Guangji Wang. Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2007, 29 (6) , 687-710.
    68. F Guengerich. Cytochrome P450 Activation of Toxins and Hepatotoxicity. 2007, 13-31.
    69. Jiansong Yang, Masoud Jamei, Karen Rowland Yeo, Geoffrey T. Tucker, Amin Rostami-Hodjegan. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. European Journal of Pharmaceutical Sciences 2007, 31 (3-4) , 232-241.
    70. Thomas M Polasek, John O Miners. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opinion on Drug Metabolism & Toxicology 2007, 3 (3) , 321-329.
    71. Nao Torimoto, Itsuko Ishii, Masayuki Hata, Yukari Kobayashi, Hiroyoshi Nakamura, Noritaka Ariyoshi, Mitsukazu Kitada. Theoretical calculation of triazolam hydroxylation and endogenous steroid inhibition in the active site of CYP3A4. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2007, 1774 (2) , 223-232.
    72. Robert J Riley, Ken Grime, Richard Weaver. Time-dependent CYP inhibition. Expert Opinion on Drug Metabolism & Toxicology 2007, 3 (1) , 51-66.
    73. Ken Thummel. Factors Influencing Drug Metabolism. 2007, 1-18.
    74. Yi-Tong Liu, Hai-Ping Hao, Chang-Xiao Liu, Guang-Ji Wang, Hong-Guang Xie. Drugs as CYP3A Probes, Inducers, and Inhibitors. Drug Metabolism Reviews 2007, 39 (4) , 699-721.
    75. Yasuhiro Masubuchi, Toshiharu Horie. Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs. Critical Reviews in Toxicology 2007, 37 (5) , 389-412.
    76. Hongjian Zhang, Donghui Cui, Bonnie Wang, Yong-Hae Han, Praveen Balimane, Zheng Yang, Michael Sinz, A David Rodrigues. Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol. Clinical Pharmacokinetics 2007, 46 (2) , 133-157.
    77. Barbara Gawronska-Szklarz, Mariusz Zarzycki, Heros David Musial, Artur Pudlo, Igor Loniewski, Marek Drozdzik. Lidocaine pharmacokinetics in postmenopausal women on hormone therapy. Menopause 2006, 13 (5) , 793-798.
    78. Xiao-Xia Yang, Ze-Ping Hu, Sui Yung Chan, Shu-Feng Zhou. Monitoring drug–protein interaction. Clinica Chimica Acta 2006, 365 (1-2) , 9-29.
    79. E. Row, S. A. Brown, A. V. Stachulski, M. S. Lennard. DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4. Drug Metabolism and Disposition 2006, 34 (2) , 324-330.
    80. . Hormonal contraceptives—oral. 2006, 1643-1678.
    81. Toshiro NIWA, Toshifumi SHIRAGA, Akira TAKAGI. Drug-Drug Interaction of Antifungal Drugs. YAKUGAKU ZASSHI 2005, 125 (10) , 795-805.
    82. H Kuhl. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005, 8 (sup1) , 3-63.
    83. Helén Tuvesson, Ingrid Hallin, Robert Persson, Birgitta Sparre, Per Olov Gunnarsson, Janeric Seidegård. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR. Drug Metabolism and Disposition 2005, 33 (6) , 866-872.
    84. Namandjé N. Bumpus, Chitra Sridar, Ute M. Kent, Paul F. Hollenberg. THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION. Drug Metabolism and Disposition 2005, 33 (6) , 795-802.
    85. Jenny H Zheng. Data from the United States Food and Drug Administration. JAIDS Journal of Acquired Immune Deficiency Syndromes 2005, 38 (Supplement 1) , S24-S26.
    86. Shufeng Zhou, Eli Chan, Wei Duan, Min Huang, Yu-Zong Chen. Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews 2005, 37 (1) , 41-213.
    87. Toshiro Niwa, Toshifumi Shiraga, Akira Takagi. Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes. Biological and Pharmaceutical Bulletin 2005, 28 (9) , 1805-1808.
    88. Toshiro Niwa, Sachiko Inoue-Yamamoto, Toshifumi Shiraga, Akira Takagi. Effect of Antifungal Drugs on Cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 Activities in Human Liver Microsomes. Biological and Pharmaceutical Bulletin 2005, 28 (9) , 1813-1816.
    89. Hiroshi Iwata, Yasuhiro Tezuka, Shigetoshi Kadota, Akira Hiratsuka, Tadashi Watabe. Mechanism-Based Inactivation of Human Liver Microsomal CYP3A4 by Rutaecarpine and Limonin from Evodia Fruit Extract. Drug Metabolism and Pharmacokinetics 2005, 20 (1) , 34-45.
    90. Shufeng Zhou, Sui Yung Chan, Boon Cher Goh, Eli Chan, Wei Duan, Min Huang, Howard L McLeod. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics 2005, 44 (3) , 279-304.
    91. Eva Tydén, Lena Olsén, Jonas Tallkvist, Pia Larsson, Hans Tjälve. CYP3A in horse intestines. Toxicology and Applied Pharmacology 2004, 201 (2) , 112-119.
    92. Tanios S. Bekaii‐Saab, Michael D. Perloff, James L. Weemhoff, David J. Greenblatt, Lisa L. von Moltke. Interactions of tamoxifen, N‐desmethyltamoxifen and 4‐hydroxytamoxifen with P‐glycoprotein and CYP3A. Biopharmaceutics & Drug Disposition 2004, 25 (7) , 283-289.
    93. Marcela Ayala, Eduardo Torres. Enzymatic activation of alkanes: constraints and prospective. Applied Catalysis A: General 2004, 272 (1-2) , 1-13.
    94. Pawel Baranczewski, Lennart Möller. Relationship between Content and Activity of Cytochrome P450 and Induction of Heterocyclic Amine DNA Adducts in Human Liver Samples In vivo and In vitro. Cancer Epidemiology, Biomarkers & Prevention 2004, 13 (6) , 1071-1078.
    95. Jyoti Kalbag, Cheryl Elder, Graham Scott, Yibin Wang, Slavica Milosavljev, Philipp Leese, Jacque Caldwell, Christiane Rordorf. Concomitant Administration of Lumiracoxib and a Triphasic Oral Contraceptive Does Not Affect Contraceptive Activity or Pharmacokinetic Profile. The Journal of Clinical Pharmacology 2004, 44 (6) , 646-654.
    96. Margit Fröhlich, Jürgen Burhenne, Meret Martin‐Facklam, Johanna Weiss, Michael Von Wolff, Thomas Strowitzki, Ingeborg Walter‐Sack, Walter E. Haefeli MD. Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. British Journal of Clinical Pharmacology 2004, 57 (3) , 244-252.
    97. Michael W. Sinz. Drug Metabolism In Preclinical Development. 2004, 75-132.
    98. Hermann M. Bolt. Rifampicin, A Keystone Inducer of Drug Metabolism: From Herbert Remmer's Pioneering Ideas to Modern Concepts. Drug Metabolism Reviews 2004, 36 (3-4) , 497-509.
    99. David M. Stresser, Marc I. Broudy, Thuy Ho, Catherine E. Cargill, Andrew P. Blanchard, Raman Sharma, Andre A. Dandeneau, Joseph J. Goodwin, Stephanie D. Turner, John C. L. Erve, Christopher J. Patten, Shangara S. Dehal, Charles L. Crespi. HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE. Drug Metabolism and Disposition 2004, 32 (1) , 105-112.
    100. Kari Laine, Ümit Yasar, Jolanta Widén, Gunnel Tybring. A Screening Study on the Liability of Eight Different Female Sex Steroids to Inhibit CYP2C9, 2C19 and 3A4 Activities in Human Liver Microsomes. Pharmacology & Toxicology 2003, 93 (2) , 77-81.
    Load more citations

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect